Urgent call for breast cancer drug to stop women’s lives being cut short

A new study has enabled scientists to study breast tissue in detail outside the body (Rui Vieira/PA) (PA Wire)

An urgent warning has been made to health officials and pharmaceutical companies to work together to make a life-extending drug available to thousands of women with incurable breast cancer.

Experts from Breast Cancer Now said that women’s lives “will be cut short” with further delays as they called for Enhertu to be made available to women in England with a certain type of breast cancer as swiftly as possible.

In March it was announced that the treatment was blocked for widespread NHS use for women with HER2-low incurable secondary breast cancer due to price issues.

The National Institute for Health and Care Excellence (Nice) said the cost the NHS was being asked to pay for trastuzumab deruxtecan – sold under the brand name Enhertu – was “too high” in relation to its benefits.

A quarter of a million people signed a petition calling for an “urgent solution” to get the treatment to women living with secondary breast cancer as soon as possible.

Enhertu is the first licensed targeted treatment for patients with HER2-low breast cancer that cannot be removed surgically or that has spread to other parts of the body, also known as metastatic breast cancer.

Breast Cancer Now said that the drugs offer women six more months to live.

breast cancer, disease, women, urgent call for breast cancer drug to stop women’s lives being cut short
A radiologist uses a magnifying glass to check mammograms for breast cancer (Copyright 2019 The Associated Press. All rights reserved.)

Women with HER2-low incurable secondary disease in Scotland currently have access to the drug, while others across the UK do not, the charity said.

Had Nice recommended the treatment, about 1,000 patients a year would have been eligible.

Baroness Delyth Morgan, chief executive at Breast Cancer Now, said: “Over a quarter of a million people have signed our Enhertu Emergency petition, rallying behind us and keeping up pressure and momentum in calling on Nice, NHS England, Daiichi Sankyo and AstraZeneca to get back around the table to reach a solution to ensure Enhertu is made available on the NHS in England for women who desperately need it.

“This must happen urgently, or women’s lives will tragically be cut short.”

Draft guidance published by Nice in September said it would not recommend Enhertu for NHS use in England due to uncertainties in the information provided by the manufacturer and called for more details.

The spending watchdog then paused its appraisal in December while commercial talks were ongoing with pharmaceutical companies Daiichi Sankyo and AstraZeneca, but in March it was announced that the talks concluded without a price agreement in place.

Breast Cancer Now said that health leaders and pharmaceutical companies should “seize the opportunity presented by the delay to Nice’s final guidance being published” to find a solution.

It is understood that talks between parties have resumed.

A letter from NHS officials sent to MPs on the parliamentary Health Committee on Tuesday stated: “We can confirm that a further discussion with all relevant parties was held on 15th May, with an expectation of flexibility from all sides. However, at this meeting Daiichi Sankyo informed us of the withdrawal of its previous commercial offer and increased the price proposal for the drug.”

Lady Morgan added: “Nice’s delay to the publication of its final guidance on Enhertu creates a crucial window of opportunity for this heart-breaking situation to be fixed now, and women with HER2-low secondary breast cancer to be granted precious hope of more time to live and to create special moments that matter.”

breast cancer, disease, women, urgent call for breast cancer drug to stop women’s lives being cut short
NHS nurse Tracy Pratt whowas diagnosed with HER2-low secondary breast cancer in November 2022 after experiencing upper back pain (Breast Cancer Now/PA Wire)

NHS nurse Tracy Pratt was diagnosed with HER2-low secondary breast cancer in November 2022 after experiencing upper back pain.

The 52-year-old from Tydd St Mary, Lincolnshire, said: “When I heard the news that it had been rejected for use on the NHS, I was in shock.

“I cried, I felt completely let down and lost, sad for me, sad for my family and sad for everyone else in the secondary breast cancer community, that this decision affects.

“Enhertu would give me more quality time to enjoy my life with my family and friends, more time to live with secondary breast cancer. It would give me more time to travel and continue to work as a nurse. Ultimately it would give me hope.

“This decision does not just affect us living with secondary breast cancer now but also those that will develop it in the future. The reality is that the decision is likely to affect you or someone you love in the future. This decision must be reversed.”

A spokesperson for Daiichi Sankyo said: “Daiichi Sankyo and AstraZeneca welcomed the opportunity to provide evidence to the Health and Social Care Committee and All Party Parliamentary Group on Breast Cancer regarding Nice’s decision to not recommend Enhertu for HER2-low metastatic breast cancer, as well as highlight our concerns regarding the impact of changes to Nice’s formula on the future launch of treatments targeting late-stage cancers.

“As committed to during the meeting we have restarted the dialogue with NHS England and Nice, and the final publication of guidance has been paused while those talks are ongoing.”

OTHER NEWS

4 hrs ago

Cowboys head coach Mike McCarthy 'getting fed up' with owner Jerry Jones: report

4 hrs ago

Who Should Steelers Hope Wins Training Camp QB Battle?

4 hrs ago

Goaltender's dad talks up the Oilers' chances of lifting the Stanley Cup

4 hrs ago

Phillies turn rare 1-3-5 triple play against Tigers, 1st since 1929

4 hrs ago

Discount Burger Check? Chiefs' Reid Shares Hilarious Commercial Story

4 hrs ago

'Devastating loss': Digital lending library, Internet Archive, removes 500,000 books after being sued by publishers

4 hrs ago

Iga Swiatek vs Coco Gauff vs Aryna Sabalenka vs Elena Rybakina: WTA ‘Big 4’ state of play ahead of Wimbledon

4 hrs ago

Would a Toronto byelection loss spell doom for Trudeau?

4 hrs ago

BlackSuit ransomware gang blamed for ongoing car dealership outages

4 hrs ago

'Unreal' injury-time equaliser saves football powerhouse

4 hrs ago

Nigel Farage accused of cosying up to the Kremlin by former NATO boss

4 hrs ago

Dagestan, in southern Russia, has a history of violence. Why does it keeps happening?

4 hrs ago

Marines revive a World War II airfield on Peleliu in Pacific pivot

4 hrs ago

Fortnite Brings Tilted Towers and Other Fan Favorite Locations, But With a Twist

4 hrs ago

Shadow of the Erdtree Puts the Cherry on Top of Elden Rings Main Strength

4 hrs ago

Anger erupts as Albo's governor-general is awarded payrise

4 hrs ago

Charo Makes Rare Public Appearance at Project Angel Food Event: 'Life Is Beautiful' (Exclusive)

4 hrs ago

Boozed-up England fans sing '10 German bombers' chant in Cologne

4 hrs ago

Show Respect: ‘Boys are surprised we talk about this, it’s become normalised’

4 hrs ago

After clash with prosecutor, judge reserves ruling on restricting Trump’s rhetoric about agents’ classified documents search

5 hrs ago

Peter Dutton’s nuclear plan ‘doesn’t deliver’ any ‘energy price decrease’ until 2040

5 hrs ago

Where to watch Netherlands vs. Austria live stream, TV channel, lineups, prediction for Euro 2024 match

5 hrs ago

China lunar probe to return to Earth with samples

5 hrs ago

Report: Knicks’ OG Anunoby declines player option, enters unrestricted free agency

5 hrs ago

Saints offensive line ranked 19th in the NFL

5 hrs ago

Senators acquire goaltender Linus Ullmark from Bruins

5 hrs ago

Why Qld feels like home for the Blues

5 hrs ago

Seahawks waive 3 undrafted free agents, make UFL champ signing official

5 hrs ago

Andrew Scott Frantically Runs to Hear Taylor Swift's ‘Style' at 'Eras Tour'

5 hrs ago

England’s Test series v New Zealand: Date, kick-off time and TV channel

5 hrs ago

Bills' McDermott Says Von Miller Has ‘Something to Prove’

5 hrs ago

US prosecutors want Boeing to face criminal charges

5 hrs ago

Finance Minister Michael McGrath set to become Ireland's new EU Commissioner

5 hrs ago

Red-hot Cardinals get huge boost in return of star catcher

5 hrs ago

How police use the mail to spy on you: 60,000 cases in last decade with little pushback

5 hrs ago

These 3 Republicans are Trump’s most likely VP picks

5 hrs ago

Roy Jones Jr. announces his son, DeAndre, died by suicide

5 hrs ago

Luxury Gyms, Like Equinox and Life Time, Are Taking Over Big Retail Spaces

5 hrs ago

Automobili Pininfarina PURA Vision wins prestigious Red Dot Award: Design Concept 2024

5 hrs ago

Pop legend Robbie Williams wears his AFL jersey to see if he still gets recognised in London - with some very surprising results